Researchers in Greater Philadelphia developing technologies for high-speed eye exams, cancer treatment and healthcare sanitation will receive funding through the seventh round of the
University City Science Center's QED Proof-of-Concept Program.
The program, started in 2009, funds novel university technologies with market potential, bridging the gap between academic research and product commercialization. To date, 24 QED projects have attracted $14.8 million in follow-on funding, leading to six licensed technologies.
"QED continues to resonate with both the academic and funding community," says Science Center President and CEO Stephen S. Tang. "The number of submissions continues to increase round over round as academic researchers identify ways to commercialize their emerging technologies. At the same time, the support of our funders enables us to continue to facilitate the development of these exciting technologies and contribute to the robust life science ecosystem in the Greater Philadelphia region."
The new awardees include:
- Dr. Chao Zhou of Lehigh University, who is developing a diagnostic instrument that will allow faster, more sensitive eye exams for macular degeneration and glaucoma, improving an approach known as optical coherence tomography (OCT).
- Dr. William Wuest of Temple University, who is developing the next generation of disinfectants for a variety of commercial industries including healthcare, transportation, water and energy.
- Dr. Sunday Shoyele of Thomas Jefferson University, who is developing a product for delivering highly-degradable gene inhibitors to cancer and other cells using antibody-based nanoparticles.
The QED grants will also support stem cell research at
Rutgers University. The awardees will receive a total of $650,000 in funding, along with guidance from the Science Center's team of business advisors.
Source: University City Science Center
Writer: Elise Vider